JC17 Rec'd PCT/PTO 04 MAY 2005
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yoshitaka MIYAKAWA, et al.

Application Serial No.: To Be Assigned

Application Serial No.: To Be Assigned

Attorney's Docket No.: 38331-0006

Filed: Herewith

Int'l. Application No.: PCT/JP2003/14149

For: Animal Model of Human
Hematopoietic Tumor

Customer No. 25213

EXPRESS MAIL LABEL NO. EL 993 639 566 US

Date Mailed: May 4, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98. In addition, enclosed is a copy of the International Search Report received in a related matter for the above-identified application which discloses the reference submitted herewith.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

10/533796

JC17 Rec'd PCT/PTC 04 MAY 2005

⊠ that ap		latemer	nt qualifies under 37 C.F.R. §1.97, subsection (b) because (check all						
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR						
		(2)	It is being filed within 3 months of entry of a national stage OR						
	\boxtimes	(3)	It is being filed before the mail date of the first Office Action on the merits OR						
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.						
	97(c). If this statement is being filed after the latest of: (1) three months ing date of a national application; (2) three months beyond the date of ational stage as set forth in §1.491 in an international application; or (3) ate of a first Office action on the merits, but before the mailing date of a final office action under §1.113 or a notice of allowance under §1.311,								
		a certif	certification as specified in §1.97(e) is provided below; or						
		a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.							
	of a fin	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:							
	A.	a certification as specified in §1.97(e) is completed below; and							
\boxtimes	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and							
	C.	a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.							
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Attorney's Docket No. 38331-0006)</u> .								
			Respectfully submitted,						
Dated:	Dated: May 4, 2005 By:								
275 Mi Menlo Teleph	iddlefiel Park, C ione: (6		a 94025-3506 4-7000						

INFO		Form PTO-1	449 JRE STATEMENT	Attorney's Docket No. 38331-0006 Applicant(s)		Application Striat 7 9 6 To Be Assigned					
				1	Yoshitaka Miyakawa, et al.						
				Filing Date:							
	(use sev	eral sheets i	if necessary)	Herewith		To Be Assigned					
			•	U.S. PATENT DOCUMENTS					_		
Examiner	Ref.	Date	Document No.	Name	Cla	ass	Subclass	Filing Date			
Initials	No.					(if appropriate		riate)			
			<u> </u>					<u> </u>			
				REIGN PATENT DOCUMEN				·			
Examiner	Ref.	Date	Document No.	Name	Cla	ass	Subclass	Translation			
Initials	No.							YES	NO		
	1.	6/6/2002	WO 02/43477 A1	PCT	A()1K	67/027	ļ	X		
		ļ							ļ		
		<u> </u>					-		<u> </u>		
				OTHER DOCUMENTS							
			(including	g author, title, date, pertinent pa	ages, etc.)						
Examiner	Ref.	Title									
Initials									\		
	2.	Mitsuyoshi Urashima, et al., "The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow", BLOOD, American Society of Hematology, Vol. 90, No. 2 (July 15), 1997; pp 754-765									
	3.	Yoshi Miyakawa, et al., "Establishment of Human Multiple Myeloma Model Using Newly Developed Immunodeficienent NOD/SCID./IL-2Rγ-/- (NOG) Mice", Abstract #2366, Poster Board #-Session 650-II, American Society of Hematology, Vol. 100, No. 11 (Nov. 16), 2002; pp. 601a.									
		1.00,1.01	учет тор, шеец, ррт с						<u> </u>		
	İ										
	<u> </u>	•									
	ļ				***						
	<u> </u>	4									
	-		· · · ·				.				
						_					
	ļ										

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).